earnings
confidence high
sentiment positive
materiality 0.75
Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt
Amneal Pharmaceuticals, Inc.
2025-Q2 EPS reported
$0.11
revenue$1,419,928,000
- Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
- Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).
- Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.
- Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.
- FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake.